Natera, Inc. (NASDAQ:NTRA) Insider Daniel Rabinowitz Sells 325 Shares

Natera, Inc. (NASDAQ:NTRAGet Rating) insider Daniel Rabinowitz sold 325 shares of the business’s stock in a transaction dated Friday, April 22nd. The stock was sold at an average price of $36.14, for a total value of $11,745.50. Following the transaction, the insider now owns 143,358 shares in the company, valued at approximately $5,180,958.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Daniel Rabinowitz also recently made the following trade(s):

  • On Thursday, March 10th, Daniel Rabinowitz sold 884 shares of Natera stock. The stock was sold at an average price of $42.16, for a total value of $37,269.44.

Shares of Natera stock traded up $3.38 on Monday, reaching $39.67. 1,162,442 shares of the company were exchanged, compared to its average volume of 2,388,439. Natera, Inc. has a 1-year low of $26.10 and a 1-year high of $129.09. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of -7.67 and a beta of 1.20. The company’s 50-day moving average is $46.49 and its two-hundred day moving average is $75.63. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.87 and a current ratio of 4.99.

Natera (NASDAQ:NTRAGet Rating) last issued its quarterly earnings data on Thursday, February 24th. The medical research company reported ($1.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.24). Natera had a negative return on equity of 90.55% and a negative net margin of 75.43%. The business had revenue of $173.00 million during the quarter, compared to the consensus estimate of $168.59 million. During the same period last year, the company earned ($0.89) earnings per share. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. As a group, sell-side analysts forecast that Natera, Inc. will post -6.05 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of NTRA. Allspring Global Investments Holdings LLC bought a new position in Natera in the 4th quarter worth approximately $379,131,000. Norges Bank bought a new position in Natera during the 4th quarter valued at $83,446,000. Farallon Capital Management LLC boosted its stake in Natera by 160.0% during the 3rd quarter. Farallon Capital Management LLC now owns 1,300,134 shares of the medical research company’s stock valued at $144,887,000 after purchasing an additional 800,134 shares in the last quarter. Invesco Ltd. boosted its stake in Natera by 30.8% during the 3rd quarter. Invesco Ltd. now owns 3,055,583 shares of the medical research company’s stock valued at $340,514,000 after purchasing an additional 718,619 shares in the last quarter. Finally, Bamco Inc. NY bought a new position in Natera during the 3rd quarter valued at $73,013,000.

Several research analysts recently commented on the company. StockNews.com assumed coverage on Natera in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. BTIG Research cut their price target on Natera from $125.00 to $100.00 in a research note on Thursday, March 10th. Wells Fargo & Company cut their price target on Natera from $135.00 to $100.00 in a research note on Monday, January 24th. Piper Sandler boosted their price target on Natera from $70.00 to $75.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 13th. Finally, Stephens initiated coverage on Natera in a research note on Monday. They issued an “overweight” rating and a $54.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $110.54.

Natera Company Profile (Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

See Also

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.